Investigation of the Benefit of Using an Autologous Platelet-rich Fibrin Matrix (Obsidian ASG®) for Treatment of Anastomosis During Rectal Surgery

NAActive, not recruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

December 23, 2021

Primary Completion Date

October 31, 2024

Study Completion Date

December 31, 2024

Conditions
Anastomotic Leak Rectum
Interventions
DEVICE

Obsidian ASG

Application of an autologous platelet-rich fibrin matrix

Trial Locations (13)

2700

Landesklinikum Wienerneustadt, Wiener Neustadt

4021

Kepler Universitätsklinikum GmbH, Med campus III, Linz

4041

Krankenhaus der Barmherzigen Brüder Wien, Vienna

8020

Krankenhaus der Barmherzigen Brûder, Graz

11000

University Hospital Belgrade, Belgrade

18016

Granada Hospital, Granada

20122

University Milano, Milan

46016

Consorci Hospital General Universitari de Valencia, Valencia

83022

RoMed Klinikum Rosenheim, Rosenheim

86152

Universität Augsburg, Augsburg

90419

Klinikum Nürnberg Nord, Nuremberg

90766

Klinikum Fürth, Fürth

01099

Diakonissenkrankenhaus Dresden, Dresden

All Listed Sponsors
collaborator

Raffeiner GmbH

INDUSTRY

collaborator

European Commission

OTHER

collaborator

AF Schimetta GMbH

UNKNOWN

collaborator

Rivolution GmbH

UNKNOWN

lead

Vivostat

INDUSTRY